Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents

Current Opinion in Oncology

Volumn 12, Issue 4, 2000, Pages 289-296

  Awada, Ahmad ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BUSULFAN; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTAMINE; IFOSFAMIDE; IRINOTECAN; MELATONIN; MELPHALAN; MESNA; NITRATE; PACLITAXEL; RAZOXANE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; FERTILITY; HYPERSENSITIVITY REACTION; LUNG TOXICITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; NEOPLASMS; PREVENTIVE MEDICINE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, ADJUVANT;

EID: 0034503032     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200007000-00003     Document Type: Review

References (43)

1. Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
2. Recommendatins for the use of antiemetics: Evidence-based, clinical practice guidelines
3. Early monocytopenia after chemotherapy as a risk factor for neutropenia
4. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: Etiology and potential risk factors
5. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
6. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children
7. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants
8. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy
9. Phase II trial of liposome encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
10. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
11. EORTC 10968: Phase I study of Caelyx at a six week interval in patients with metastatic breast cancer
12. Whole blood harvested after granulocyte-CSF (Neupogen) and retransfused without cell separation after high dose chemotherapy for various cancers results in rapid engraftment
13. Low-energy He/Ne laser in the prevention of radiation-induced mucositis: A multicenter phase III randomized study in patients with head and neck cancer
14. Laser effects on oral mucositis in patients receiving chemotherapy
15. Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines
16. Analyse de la prescription de facteurs de cipissance hématopoiėtique dans 19 centres anticancéreux français
17. Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia
18. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF
19. Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I)
20. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors
21. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer
22. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
23. Amifostine (AMI) cytoprotection (CP) of escalating doses of mefphalan (MEL) and autologous hematopoietic stem cell transplantation (AHSCT): A phase I-II study
24. A phase I double-masked, placebo-controlled study to evaluate tolerability of neumega (rhIL-11; oprelvekin) to reduce mucosistis in patients with solid tumors of lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT)
25. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) mouth-wash on grade III chemotherapy-induced oral mucositis
26. Amifostine reduces severe esophagitis during concurrent chemotherapy with weekly paclitaxel and thoracic irradiation in patients with locally advanced non-small cell lung cancer
27. Reduction of chemotherapy-induced side effecs by parenteral glutamine supplementation in patients with metastatic colorectal cancer
28. Activity of orally administered budesonide (BUD) in patients with irinotecan (CPT-11) induced diarrhea
29. Glutamine treatment of paclitaxel-induced myalgias and arthralgias
30. Use of gabapentin to treat taxane-induced myalgias
31. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias
32. Double blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advance lung cancer
33. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
34. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy
35. High dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients
36. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: A case report
37. A phase I trial of topical topitriol (calcitrol,1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia
38. Clinical features of hypersensitivity reactions to carboplatin
39. Anaphylaxis after oxiplatin
40. Incidence, course, and severity of taxoid induced hypersensitivity reaction in 646 oncology patients
41. Inhaled steroids significantly reduce delayed pulmonary toxicity syndrome following high-dose chemotherapy and autologous bone marrow transplantation
42. High-dose leucovorin as sole therapy for methotrexate toxicity
43. Cell death genes may hold clues to preserving fertility after chemotherapy